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Abstract
Resistance to antibiotics has increased dramatically over the past few years and has now reached a level that
places future patients in real danger. Microorganisms such as Escherichia coli and Klebsiella pneumoniae, which are
commensals and pathogens for humans and animals, have become increasingly resistant to third-generation
cephalosporins. Moreover, in certain countries, they are also resistant to carbapenems and therefore susceptible
only to tigecycline and colistin. Resistance is primarily attributed to the production of beta-lactamase genes located
on mobile genetic elements, which facilitate their transfer between different species. In some rare cases, Gram-
negative rods are resistant to virtually all known antibiotics. The causes are numerous, but the role of the overuse
of antibiotics in both humans and animals is essential, as well as the transmission of these bacteria in both the
hospital and the community, notably via the food chain, contaminated hands, and between animals and humans.
In addition, there are very few new antibiotics in the pipeline, particularly for Gram-negative bacilli. The situation is
slightly better for Gram-positive cocci as some potent and novel antibiotics have been made available in recent
years. A strong and coordinated international programme is urgently needed. To meet this challenge, 70
internationally recognized experts met for a two-day meeting in June 2011 in Annecy (France) and endorsed a
global call to action ("The Pensières Antibiotic Resistance Call to Action”). Bundles of measures that must be
implemented simultaneously and worldwide are presented in this document. In particular, antibiotics, which
represent a treasure for humanity, must be protected and considered as a special class of drugs.
Keywords: antibiotic resistance, antibiotic stewardship, infection control, hand hygiene, surveillance networks, care
bundles, environment, regulations, human medicine, animal medicine
Background
In the golden age of the discovery of antibiotics, these
potent “miracle” drugs saved millions of lives. In con-
trast, we are entering an era where bacterial infections,
such as bloodstream infections and ventilator-associated
pneumonia, might no longer be successfully treated with
antibiotics [1]. We now face a dramatic challenge result-
ing from two combined problems. First, microorganisms
are becoming extremely resistant to existing antibiotics,
in particular Gram-negative rods (e.g., Escherichia coli,
Salmonella spp, Klebsiella spp, Pseudomonas aeruginosa,
Acinetobacter spp), which are resistant to almost all cur-
rently available antibiotics in some settings. Resistance
can be combined with virulence, acting as a potentially
deadly duo, as observed in the recent large epidemic
outbreak of E. coli 0104:H4 in Europe, notably in Ger-
many [2]. Second, the antibiotic pipeline has become
extremely dry [3]. Several new powerful compounds
active against Gram-positive cocci have been made
available in the last few years, but this is not the case
for Gram-negative bacteria and almost no new antibiotic
class active against multiresistant Gram-negative rods
can be anticipated in the near future. Although hard to
imagine, the reality is that many clinicians will soon face
a therapeutic dead end in the treatment of certain types
of severe bacterial infections. This worrisome situation
takes us back to the pre-antibiotic era of the 1930s and
early 1940s [1,3,4]. We cannot look at this evolving and
pandemic threat passively and lose one of the most
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important drugs discovered in the previous century. We
must act now; silence is not an answer.
In this position paper, we summarize important mes-
sages and conclusions from the 3rd World Healthcare-
Associated Infections (HAI) Forum held in June 2011.
The meeting gathered together 70 leading world experts
and opinion leaders in the domain of antimicrobial
resistance (AMR) from 33 countries to discuss the chal-
lenges and possible options to tackle the problem. The
main objectives were to structure and propose a hierar-
chy of the various measures reported in the recent lit-
erature and to collect information on the experiences of
the many countries represented to discuss if some may
be transposable to other nations.
What are the facts about AMR?
Many alarming facts regarding AMR have accumulated,
particularly over the last few years.
– An increase in global resistance rates in many bac-
terial species responsible for both community- and
healthcare-related infections, e.g., staphylococci, entero-
cocci, gonococci, and enterobacteria (including E. coli,
Salmonella spp and Shigella spp), Pseudomonas spp,
Acinetobacter spp, and Mycobacterium tuberculosis)
[1,5-7].
– The burden of bacteremias due to E. coli, one of the
most common human pathogens, is increasing in Eur-
ope, mainly due (but not only) to resistant strains [7].
– Emergence and dissemination of new mechanisms
of resistance, e.g., novel extended-spectrum beta-lacta-
mases (ESBL) and carbapenemases [8-12]. The spread of
the new resistance gene, the New Delhi metallo-beta-
lactamase 1 (NDM-1), or other carbapenemases in
Enterobacteriacae is alarming because these “superbugs”
are resistant to most available antibiotics and can disse-
minate worldwide very rapidly, in particular as a conse-
quence of medical tourism [12].
– The rapid increase in the multiresistance of Gram-
negative rods stands in contrast to a steady decrease in
methicillin-resistant Staphylococcus aureus (MRSA)
rates following the implementation of successful infec-
tion control programmes in several high-income coun-
tries, such as Belgium, France, United Kingdom (UK),
and the USA [13-15]. In some other countries, resis-
tance to both Gram-positive and -negative bacteria is
very high (USA for community-acquired (CA)-MRSA;
Greece, Italy, Portugal, UK, the USA, and many eastern
European and Asian countries for vancomycin-resistant
enterococci [VRE]).
– Propensity to use last-line therapy (e.g., carbape-
nems) to treat healthcare-related and community-
acquired infections triggered by a fear of infections
caused by ESBL-producing Enterobacteriaceae, despite
the fact that these antibiotics should be preserved as our
last weapons against multiresistant Gram-negative
bacteria.
– Re-use of old drugs with poor safety and efficacy
profiles and uncertain pharmacokinetic/pharmacody-
namic characteristics (e.g., colistin) due to a lack of
alternative drugs [16].
– High morbidity and mortality attributable to multi-
resistant bacteria in critically ill patients.
• In Europe, the European Centre for Disease Pre-
vention and Control (ECDC) reported that 25,000
people die each year from antibiotic-resistant bac-
teria [17].
• In the USA, MRSA is associated with a staggering
90,000 infections and an estimated 19,000 deaths
annually [18].
– Serious financial consequences of bacterial
resistance.
• Multidrug-resistant organisms (MDROs) result in
massive extra healthcare costs and productivity losses of
at least 1.5 billion euros each year in Europe [17].
• In the USA, the annual cost of AMR in hospitals is
estimated at more than US$ 20 billion with an even
wider clinical impact than human immunodeficiency
virus (HIV)-related disease [19].
However, these data on morbidity, mortality, and cost
must be considered with caution and may be over- or
underestimated because of a lack of in-depth adjustment
for risk factors or evaluation of the indirect costs of
AMR. Moreover, these figures were calculated before
the pandemic with multiresistant Gram-negative rods.
Therefore, morbidity, mortality, and the associated eco-
nomic burden are very likely to increase dramatically
during the next decade [20]. Furthermore, with the cur-
rent European financial crisis resulting in massive cuts
in healthcare expenditure and medical research, we can
expect multiresistant bacteria to spread more rapidly in
hospitals.
What are the causes of this frightening evolution?
The most important cause is that there has been a mas-
sive overuse of antibiotics worldwide across all ecosys-
tems over the past decades, including humans, animals,
aquaculture, and agriculture (Additional files 1 &2).
When selected silently by antibiotics, a hidden cross-
transmission of resistant bacteria occurs daily, both in
hospitals and communities. Compliance with hand
hygiene practices is far from optimal in many healthcare
settings, including hospitals and long-term care facilities
[21], thus resulting in a continuous succession of small-
size transmission events difficult to detect, as well as
large outbreaks. Exchange of resistant bacteria via travel
activities and patient transfers has led to a rapidly
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growing “resistance globalization” as recently exempli-
fied by the spread of NDM-1 [8]. As a consequence,
some countries recommend the preemptive isolation of
patients admitted from outside their borders based on a
suspicion of MDRO carriage in the same philosophy as
the “Search and Destroy” programme in The Nether-
lands [22]. Cross-transmission occurs also in community
settings (e.g., schools, families, daycare centres). Finally,
hospital and community wastewater systems are an
additional source for the dissemination of resistant
bacteria.
In particular, the spread of antibiotic-resistant Entero-
bacteriaceae insensitive to third-generation cephalospor-
ins and carbapenems poses a serious public health
threat. Resistance to these beta-lactams is primarily
attributed to the production of beta-lactamases, ESBLs
and carbapenemases, respectively, and their coding
genes located on mobile genetic elements (e.g., plas-
mids) facilitate intra- and interspecies transfer.
Many countries and healthcare facilities still lack effec-
tive antibiotic stewardship programmes [23]. Antibiotics
continue to be considered as “ordinary” drugs and are
prescribed freely by many different physicians, both in
the community and in hospitals. In general, these physi-
cians lack appropriate and rigorous training in infectious
diseases and prescribe without any control or help.
When national or local programmes do exist, they have
often transient effects and require sustained and
repeated incentives. As an example, the “Antibiotics are
not automatic” ("Les antibiotiques, c’est pas automa-
tique”) programme launched in France in the early
2000s had a very positive effect during five years (23%
overall decrease in consumption) [24], but consumption
is now again on the rise [25]. Self-medication, an impor-
tant driver of antibiotic overuse, is common, particularly
in developing countries where antibiotics can be bought
over the counter in pharmacies or in local market
places, but it occurs also in Europe, mainly in southern
and eastern countries [26]. Antibiotics are used in
excess, particularly for common colds and upper
respiratory tract syndromes that are mostly of viral ori-
gin. Direct sales via the internet are also increasing and
difficult to control [27], including sales in some coun-
tries of illegal over-the-counter antibiotics and counter-
feit drugs that may contain sub-optimal active antibiotic
concentrations.
Simultaneously, the antibiotic pipeline is drying up for
two reasons (Additional file 3): 1) it is intrinsically diffi-
cult to find new antibiotics with novel mechanisms of
action; and 2) a high cost/benefit and risk/benefit ratio
(length of development, low selling prices, and short
treatments) discourage pharmaceutical companies from
investment. Moreover, bacteria are rapidly developing
when antibiotics are overused, which creates a dilemma
for the profit-driven pharmaceutical industry. Therefore,
new business models must be developed to encourage
research and development arms of companies to engage
in the discovery of new antibiotics, but these discussions
have turned out to be very difficult. In addition, the
financial crisis will probably increase the burden on tax
payers and industry to invest in this field.
Is there any national or international reaction to this
threat?
Many national/international meetings, workshops, and
task forces, as well as reports in the scientific literature
and lay press, have been dedicated to this threat over
the last decade, particularly in 2011, but often with a
limited impact due to a lack of coordination
[17,18,28-34]. Only a few developed countries worldwide
[13-15,35-37] have managed to reduce antibiotic con-
sumption in the community and/or successfully imple-
mented hand hygiene campaigns in their hospitals,
which have sometimes resulted, but not always, in a
decrease in resistance. However, despite these efforts,
resistance among Gram-negative rods has increased dra-
matically in parallel, while co-existing with good results
for the decrease of MRSA infection [14].
Europe, in particular through the European Union
(EU) Directorate General for Health and Consumers
(DG SANCO; http://www.ec.europa.edu/dgs/health_-
consumer/) and the ECDC http://www.ecdc.europa.eu,
supports and organizes comprehensive and well-vali-
dated surveillance networks for AMR and antibiotic
consumption, which has allowed to monitor the impact
of these interventions [6,38]. ECDC and the European
Medicines Agency (EMA; http://www.ema.europa.eu)
have jointly organized a meeting and urged pharma-
ceutical companies to accelerate the search for new
antibiotics [17]. In 2009, a Transatlantic Taskforce for
Antimicrobial Resistance (TATFAR; http://ecdc.europa.
eu/en/activities/diseaseprogrammes/tatfar/pages/index.
aspx?MasterPage=1) was established during the Swed-
ish EU presidency to promote a mutual understanding
of US and European activities and programmes related
to AMR issues [39]. A list of 17 recommendations was
generated in 2011, but with no incentives on how to
reach its stated objectives and no mandate to address
the global aspects of this problem http://ecdc.europa.
eu/en/activities/diseaseprogrammes/tatfar/documents/
210911_tatfar_report.pdf.
Regional and international networks or alliances have
been developed also with various actions proposed, i.e.,
Action on Antibiotic Resistance (REACT; http://www.
reactgroup.org), Alliance for the Prudent Use of Anti-
biotics (APUA; http://www.tufts.edu/med/apua/), the
European Society for Clinical Microbiology and Infec-
tious Diseases (ESCMID) Study Group on Antibiotic
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Policies (ESGAP; http://www.escmid.org/research_pro-
jects/study_groups/esgap/) [40], and the Alliance against
MDRO [41]. Finally, in 2011, the World Health Organi-
zation (WHO) dedicated the World Health Day to the
topic of antimicrobial resistance with the aim to high-
light it as a global threat and to call for consolidated
efforts to avoid regressing to the pre-antibiotic era
http://http//:www.who.int/world-health-day 2011/en/
index.html. Hopefully, this will be the starting point for
tangible and sustained efforts by WHO through a
worldwide campaign.
Are we ready for a world without antibiotics?
The answer is clearly no! Today, antibiotics are critical
to treat bacterial infections. Indeed, there are very few
therapeutic compounds, if any, able to modulate the
inflammatory burst during severe sepsis [42]. Anti-toxin
therapy could represent a key component of the antibac-
terial armamentarium of the future, but it is too early to
rely on this solution on a routine basis [43]. Antimicro-
bial peptides are deceiving, particularly when used intra-
venously [44]. Bacteriophages are tempting, but are not
usable by the intravenous route and have not been care-
fully evaluated so far [45]. Resistance is also an issue
with this strategy. Some plants or aromatic substances
(e.g., essential oils) may have very interesting antibacter-
ial and antitoxin activities, but again we are far from
their use in daily practice [46]. Probiotics have been
mentioned as a possible alternative, but could be consid-
ered today more as a complement than as a real thera-
peutic solution. Vaccination is certainly the most
promising preventive strategy, but remains limited to a
relatively small number of bacteria [47], although there
are promising new vaccines entering phase III studies
against S. aureus and Clostridium difficile. Without any
doubt, antibiotics remain the cornerstone of antibacter-
ial management and they are still acutely needed for the
next generations. It is our duty to protect them.
Can we rely on recent positive and transposable
programmes?
The answer is clearly yes, but the examples are few.
Education, legislation, and improved diagnosis can
reduce antibiotic consumption. Several clinical trials at
the community level, have shown that patient education
can result in the decrease of the use of antibiotics [48].
The Patients for Patient Safety branch of the WHO
Patient Safety Programme has shown that patients can
and should have a very active role in making healthcare
safer and will be examining how to integrate informa-
tion on antibiotic resistance within its global training
group for 2012 http://www.who.int/patientsafety/patient-
s_for_patient/en/. The EU has established a strategy
against AMR to encourage the prudent use of these
agents in human medicine. Several countries have
launched national campaigns to educate physicians and
patients about antimicrobial misuse and the threat of
resistance.
The French campaign, often considered as a model,
exceeded expectations with a 23% reduction in the num-
ber of antibiotic prescriptions over the first five years [24].
However, nine years after the launch, there are still major
concerns about the way in which physicians and patients
in France prescribe and consume antibiotics. Despite the
sharp reduction of antibiotic prescriptions observed, espe-
cially among children, France remains a high user of anti-
biotics, just behind Greece and Cyprus [6,7].
The Belgian Antibiotic Policy Coordination Commit-
tee (BAPCOC) organized several national campaigns,
financially supported by the government. These multi-
media campaigns, launched in 1999 and targeting the
general public, resulted in a 36% decrease in antibiotic
prescription in the community between 1999 and 2007
[35] and decreased antibiotic resistance in Streptococcus
pneumoniae and S. pyogenes. The hand hygiene cam-
paigns, launched in 2005 and targeting patients admitted
to hospital and healthcare workers, resulted in an
increase in hand hygiene compliance and alcohol-based
handrub use in hospitals and decreased hospital-
acquired (HA)-MRSA.
However, some national campaigns, e.g., Australia,
England, Greece, and Spain, have failed to show a major
impact on antibiotic prescriptions [35]. In the USA,
some very positive results have been obtained for HA-
MRSA, but not for CA-MRSA, VRE, and ESBL-carrying
Enterobacteriaceae [48]. In Israel, some interesting
results have been obtained in the use of antibiotics in
children [22] and the successful containment of the pan-
demic with Gram-negative rods [49]. To control self-
medication, the Chilean Ministry of Health has strictly
enforced existing laws restricting the purchase of anti-
biotics without medical prescription since 1999. These
regulatory measures have resulted in a 43% decrease in
antimicrobial use in the outpatient setting, which repre-
sents a remarkable result [50]. Further interesting results
from other countries were highlighted by poster presen-
tations displayed during the meeting and are discussed
by Jarlier et al in this issue [51].
Nevertheless, despite targeted information and aware-
ness-raising campaigns, the general public has still pre-
conceived ideas concerning antibiotics and their effects.
For example, according to a Pan-European survey pub-
lished in 2010, 53% of Europeans still believe that anti-
biotics kill viruses and 47% that they are effective
against colds and influenza. Large variations between
countries were observed and knowledge increased in
countries with targeted media campaigns, such as Bel-
gium. Education remains an immense challenge [52].
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Time for international coordinated actions to save
antibiotics
In response to this global public health threat, 70 lead-
ing international experts formulated “The Pensières
Antibiotic Resistance Call to Action” during a two-day
meeting held in Annecy (France) in June 2011. Lectures
were given on a wide range of topics with extensive and
in-depth discussion. Each participant presented data and
the results of country-specific intervention programmes
targeted at the control of AMR and healthcare-asso-
ciated infection, such as infection prevention and con-
trol and antibiotic stewardship strategies. Thirty-four
posters provided for the first time a unique overview of
actions and policies in place worldwide in 29 countries
with an evaluation of their degree of efficacy. At the end
of the meeting, participants were asked to rank a series
of 25 actions linked to the topics highlighted using a
multi-voting system [51].
A coordinated programme based on six main lines of
action was defined as follows: 1) a worldwide upgrade in
infection control practices to limit resistant bacteria
cross-transmission; 2) a worldwide antibiotic steward-
ship strategy to decrease antibiotic pressure on bacteria;
3) the improved use of diagnostic techniques; 4) an
acceleration in the discovery and development of new
antibiotics, particularly targeting Gram-negative bacteria;
5) the acceleration of vaccine development programmes,
and 6) a strong educational programme for both health-
care practitioners, consumers, and children.
The programme is conceived as a “bundle” whose dif-
ferent components should be implemented simulta-
neously. Implementing only one line of action or
selecting only some components will very likely lead to
failure. Such a multifaceted programme looks easy to
implement, but is in fact a serious challenge. Although
the multiple actors to involve have different back-
grounds and interests, such as the hospital, community,
and human and animal medicine, and may not work
spontaneously together, cooperation between all is the
key to success.
A strong political commitment at international,
national, and local levels is of paramount importance to
trigger such an ambitious programme. This is absolutely
essential. Recent national or international programmes
should be evaluated. Healthcare professionals will need
the strong involvement of policy makers through to hos-
pital managers to ensure its adoption. It will take many
years to obtain significant results and we will certainly
never return to the pre-antibiotic era where all patho-
gens were fully susceptible to antibiotics. But we have
no choice and must preserve antibiotics for the next
generations. We must realize also that such a pro-
gramme is not aiming at simply saving money–and
could even increase healthcare costs initially–but it will
become eventually cost-effective when taking a long-
range perspective.
Effective infection control programmes must be
implemented worldwide
The importance of a coordinated programme combining
infection control with other actions in a rational and
sustainable manner, e.g., antibiotic stewardship, must be
strongly emphasized. Prevention of cross-transmission
and epidemics must be based on a multifaceted strategy
that should include appropriate screening policies, use
of universal precautions, improved hand hygiene, parti-
cularly through the systematic recourse to alcohol-based
handrub formulations (ABHRs), and specific contact
precautions when appropriate (i.e., geographic isolation
measures and cohorting). However, several of these
measures remain controversial and costly. For instance,
it remains unknown if specific isolation precautions are
better than standard precautions if the latter are strictly
and permanently applied, which so far is hard to obtain
[53]. Rapid diagnostic methods are needed more than
ever to detect patients colonized by MDROs and the
Innovative Medicines Initiative (IMI; http://www.imi-
europa.edu) is investing 15 million euros in the RAPP-
ID project (Development of Rapid Point-of-Care Test
Platforms for Infectious Diseases; http://www.rapp-id.eu)
to develop new diagnostic tools for bloodstream infec-
tions, lower respiratory tract infections, and tuberculosis.
It is to be hoped that some promising ongoing EU-
funded projects will help to find new solutions, e.g.,
“Mastering hOSpital Antimicrobial Resistance”
(MOSAR; http://www.Mosar-sic.org); “Impact of Specific
Antibiotic Therapies on the prevalence of hUman host
ResistaNt bacteria” (SATURN; http://www.saturn-pro-
ject.edu); and “Resistance in Gram-Negative Organisms:
Studying Intervention Strategies” (R-GNOSIS; http://
www.r-gnosis.eu).
Successful measures for controlling MRSA are prob-
ably not sufficient to prevent the spread of ESBL or car-
bapenemases for several reasons: far higher bacterial
load in the gut for Gram-negative rods; fecal excretion;
dissemination through waste; transferable resistance
genes on plasmid or transposons; lack of effective deco-
lonization regimens; or the substantial role of antibiotic
selection pressure by commonly misused drugs.
Although MRSA bloodstream infections are decreasing
in many European countries, infections due to ESBL-
producing Gram-negative rods are increasing in these
same countries. To succeed in combating these Gram-
negative rods, there is a need to upgrade and tailor the
prevention of cross-transmission outside hospitals (e.g.,
in nursing homes, families, daycare centres, and schools)
and to take into account environmental aspects. More-
over, those actors with an important role to play, such
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as specialists in infection control and healthcare man-
agers, have been somewhat paralyzed in front of the
ESBL invasion, although sometimes simultaneously very
active against MRSA or VRE.
The WHO Global Patient Safety Challenge “Clean
Care is Safer Care” is a striking example of a pro-
gramme that could provide guidance, boost hand
hygiene promotion initiatives worldwide, including in
developing countries. Proof of effectiveness of additional
actions will hopefully be provided by ongoing studies
[21]. Quality indicators are needed to assess the perfor-
mance of hand hygiene procedures in hospitals, e.g., sur-
rogate markers such as the volume of ABHR
consumption (used in France, Belgium, and Germany)
or, even better, the compliance rate with procedures (e.
g., in Australia) as proposed by the WHO strategy [54].
Population migration and health tourism are unavoid-
able components of the modern era. Hospitals accepting
international patients must follow excellent infection
control practices and antibiotic stewardship policies in
practice and not just on paper, including qualified and
trained infection control teams and a hospital manage-
ment willing to accept their recommendations.
Active protection of antibiotics (part of the so-called
“antibiotic stewardship”)
Antibiotics are natural gifts belonging to humanity and
strategies for their active protection must be developed
in a philosophy of “sustainable development” [1]. A
worldwide implementation of antibiotic stewardship
programmes is of paramount importance [23,55]. This
should be based on a multidisciplinary approach aimed
at the optimal selection, dosage, and duration of antimi-
crobial treatment resulting in the best clinical outcome
for treatment or prevention of infection with minimal
toxicity to the patient, and minimal impact on subse-
quent resistance. The reason for the prescription and
the planned duration of therapy (as well as diagnosis
whenever possible) should be indicated on every patient
chart. Indeed, in some countries, including the EU,
many hospital physicians prescribe antibiotics without
mentioning the reason in the patient notes [56]. Finally,
some antibiotics should probably be reserved exclusively
for human usage. However, there is no consensus with
the veterinary world on this measure.
A concerted international programme should induce a
marked decrease in the overall consumption of antibio-
tics in every sector of human and animal medicine,
aquaculture, and agriculture. There is no specific culprit
and all antibiotic prescribers must work together. A
strong and sustained cooperation between healthcare
professionals and consumers (antibiotic users) in an eco-
logical and civic attitude is pivotal for the success of
these programmes. Antibiotics must be considered as a
specific class of drugs [40,57], a central concept that will
have many consequences in terms of legislation, particu-
larly at the European level. A major breakthrough would
be obtained if antibiotics could be included in the Uni-
ted Nations Educational, Scientific and Cultural Organi-
zation (UNESCO) global heritage list for humanity to
demonstrate and raise awareness of their long-term
importance for human health http://www.whc.unesco.
org. Finally, it is of paramount importance to realize
that in many countries there is a very limited access to
antibiotics, which impairs safety of care. A balance
between appropriate usage and access to antibiotics is
needed. These two actions are not mutually exclusive,
but complementary.
Diagnosis of bacterial infection and antibiotic resistance
must be more rapid
Rapid diagnostic tests should be urgently developed to
help physicians to target the organisms causing the
infection. Physicians should not rely only on fever,
which is very often due to non-bacterial infections, to
prescribe antibiotics. Unfortunately, microbiology diag-
nostic techniques have not evolved much since Pasteur
and others were able to grow bacteria at the end of the
19th century, and many of their culture methods are still
used today in our routine clinical diagnostic
laboratories.
New rapid diagnostic tools, such as point-of-care test-
ing or biomarkers, should be used more widely. These
are already available for several microorganisms, includ-
ing C. difficile and MRSA. Simple tests are available to
detect Streptococcus pyogenes in the throat, but often
not used by general practitioners (5 to 15% in adults;
30% in children [58]. Urinary sticks are sensitive enough
to avoid treating most patients with a suspicion of urin-
ary tract infection, particularly in long-term care facil-
ities. Procalcitonin can help to differentiate viral and
bacterial bronchitis [59].
The development of new tools should be encouraged
to help clinicians not to treat patients with antibiotics
when bacterial infection is ruled out or, conversely, to
help them to prescribe the right antibiotic through rapid
identification of the bacteria involved and its antibiotic
susceptibility. Re-evaluation of therapy at days two or
three should be systematic in all types of practice.
Appropriate biomarkers [60] and therapeutic algorithms
that include de-escalation strategies will help to reduce
the length of therapy and optimize the choice of drugs
[61]. After a long period where antibiotic therapy has
been mostly empiric in many countries, including the
USA, it is time to teach and treat infectious diseases
based on diagnostic evidence. This will represent a dra-
matic change in our paradigm of care and a real
challenge.
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New antibiotics are urgently needed and must be
efficiently protected
WHO, TATFAR, the Infectious Diseases Society of
America (IDSA), and European institutions, as well as
healthcare professionals, have proposed measures and
incentives to fix the broken antibiotic pipeline and
encourage biotechnology and pharmaceutical companies
to invest in the development of new antibacterial agents,
particularly against Gram-negative bacteria. In 2010,
IDSA launched a new initiative entitled “10 × 20” to
mobilize key leaders, research institutions, and scientific
associations to create an antibacterial research and
development enterprise powerful enough to produce 10
new antibiotics by the year 2020 http://www.idsociety.
org/10x20/[62]. Fast-track designation for the develop-
ment of new drugs (similar to orphan drugs) to help get
them earlier to the patient, high prices for antibiotics
with a high value compared to others, including active
protection and follow-up, are actions that will help to
develop new drugs and protect them when marketed.
Prolongation of antibiotic patents has been proposed,
but remains controversial [63]. The IMI and the Eur-
opean Federation of Pharmaceutical Industries and
Associations (EFPIA; http://www.efpia.org) are currently
discussing mechanisms to jointly develop new
antibiotics.
A strong educational programme must be made available
worldwide for both healthcare professionals and
consumers
It is of paramount importance that both professionals
and consumers understand that the two main causes of
antibiotic resistance are their overuse in both humans,
animals, and agriculture. A complicity between these
two groups is key to the success of such a programme.
We need also to provide information to children and to
promote and establish large programmes such as the
Pan-European e-Bug project http://www.e-bug-edu
[64,65]. In turn, these children will teach their parents
and other family members and will become more clever
consumers of healthcare than we have ever been.
Conclusion
We have overused and abused antibiotics in both
humans and animals with huge variations between
countries [66]. Today, we have regular and precise bar-
ometers to survey resistance levels and antibiotic con-
sumption [67]. Resistance of bacteria to antibiotics has
reached levels that place the human race in real danger.
Immediate, vigorous, and coordinated measures must be
taken worldwide to save and protect the erosion of
existing antibiotics and facilitate the appearance of new
and potent antibiotics, active in particular against Gram-
negative bacilli [68,69]. This will need a profound
change in the way we diagnose and treat infectious dis-
eases [70]. Dramatic change will be needed also in the
way we behave in hospitals and in the community con-
cerning both antibiotic therapy and infection prevention
and control measures [71]. Educational programmes tar-
geting both healthcare professionals and consumers,
including children, are urgently needed. A strong coop-
eration and complicity between healthcare providers,
including researchers and consumers, is the real key to
success.
Additional file 1
Antibiotic use, misuse, and abuse
Half of all antibiotic consumption may be unnecessary
and greatly contributes to increasing bacterial resistance
[28]. In Europe (29 countries), the overall human con-
sumption of antimicrobials was 3350 tons in 2007 [29].
Outpatient consumption varies widely from 11 defined
daily doses (DDD) per 1000 inhabitants in The Nether-
lands to 34 DDD per 1000 inhabitants in Cyprus [38].
In the USA, 3300 tons of antibiotics were sold [18].
Antibiotics are ineffective against viral infections
• But they are often prescribed for self-limiting ill-
nesses, such as colds and influenza, caused by
viruses that will not respond to antibacterial drugs.
• Diagnostic uncertainty is a key driver of drug mis-
use and overuse. Since classical laboratory methods,
based on culture of the pathogenic agent, require
36-48 hours to provide results, few infections are
accurately diagnosed.
• In the absence of a clear diagnosis, physicians
often prescribe antibiotics just “to be on the safe
side” or to prevent possible secondary bacterial
infections.
• In addition, patients often put pressure on physi-
cians. In a survey conducted in the USA, nearly half
(48%) of respondents indicated that they expected an
antibiotic when they visit a doctor [72] In another
survey, more than 50% of French interviewees
expected an antibiotic for the treatment of influ-
enza-like illness [73].
It is often falsely assumed that inappropriate use of
antibiotics cannot harm
• According to the US Centers for Disease Control
and Prevention (CDC), an estimated 150,000 cases
per year present to US emergency departments for
antimicrobial-related adverse events [74].
• Incorrect use of antibiotics accelerates AMR. In
this respect, AMR is like pollution: it has so little
immediately perceptible effect that in the absence of
regulation, nothing changes [75].
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Patient compliance with recommended treatment is
another major problem
• Patients forget to take medication or may be
unable to afford a full course. They tend to consider
antibiotics as antipyretics that treat symptoms and
stop taking them as soon as they feel better.
Self-medication is also an important driver of antimi-
crobial overuse
• It has been observed in the USA [76] and Europe
[77,78], particularly for self-limiting illnesses mostly
caused by viruses.
• It is especially prevalent in developing countries
where antibiotics can be bought over the counter in
pharmacies or even in the local market place.
• Sales via the internet drive self-medication; they
are on the rise and difficult to control [27].
Additional file 2
Antibiotic use in animals: a major concern for public
health and the environment
Resistance to antibiotics is increasing both in commen-
sal and pathogenic bacteria, raising an emerging threat
to public health and the environment. Antimicrobial
administration to food animals is among the most
important factors contributing to the selection of anti-
microbial-resistant bacteria that can be transmitted from
animals to humans. More than half of all antibiotics
produced globally are used in animals [29]. In the USA
alone, animal agriculture consumes 80% of all antibiotics
used [79]. According to a first-ever estimate of the Food
and Drug Administration (FDA), the amount of antibio-
tics sold for use in food animals in the USA was over
13,000 tons (29 million pounds) in 2009 [80]. The over-
all national sales of veterinary antimicrobials in 10 Eur-
opean countries was approximately 3500 tons of active
substance in 2007 [29]. In 2009, French sales of veterin-
ary antimicrobials were 1067 tons [81].
Antimicrobial use and animal husbandry
Antimicrobials are used by veterinary practitioners for
the treatment and control of infectious diseases in a
wide variety of farm and companion animal species.
Antibiotic treatment of sick animals is common prac-
tice. When a certain percentage of farm animals or cer-
tain species (e.g., flocks of broiler chickens or salmon
pens) are affected, the entire group is treated, including
animals that are not infected. Sub-therapeutic levels of
antibiotics are also administered to animals for the pre-
vention of bacterial infections to compensate poor pro-
duction practices, often without prescription.
Low levels of antibiotic agents are frequently added to
animal feed for growth promotion in livestock (mostly
in the production of pigs, broiler chickens, turkeys, and
feedlot cattle) [82]. This is particularly problematic
because antibiotic growth promoters are used without
veterinary prescriptions or administered for long periods
of time at sub-therapeutic concentrations to entire
groups or herds of animals. This favours the selection
and spread of resistant bacteria [83].
National legislation
On January 1 2006, the EU banned the feeding of all
antibiotics and related drugs to livestock for growth pro-
motion purposes [84]. The USA has not yet implemen-
ted similar control policies for antibiotic use in animal
agriculture. However, a recently issued FDA Guidance
to Industry called for the use of antibiotics in food-pro-
ducing animals only when needed to ensure animal
health, including phasing in veterinary oversight and
consultation, and has attracted growing support within
Congress for new legislation [85,86].
Transmission of resistant bacteria from animals to
humans
Widespread use of antimicrobials for disease control and
growth promotion in animals has been paralleled by an
increase in resistance in those bacteria in animals. Resis-
tant bacteria then spread among groups of animals,
including fish, or to the local environment (adjacent
soil, air, and water) through the spreading of manure.
– Through long-term survival and transfer of resistant
genes to the resident flora [87] Studies carried out in
The Netherlands have shown that the proportion of
resistant bacteria containing antibiotic resistance genes
in the soil has significantly increased since 1940 [88].
– Through direct contact between farm animals and
humans (e.g., farmers, farm visitors) The same strains of
MRSA have been found in livestock and livestock work-
ers in The Netherlands, Italy, Canada and the USA
[89-91].
– Through contaminated food
Although correct cooking kills bacteria, contamination
can occur through improper handling before cooking.
Many of the antimicrobial-resistant E. coli strains that
cause urinary tract and bloodstream infections in
humans appear likely to have been acquired from con-
taminated retail meat.
In The Netherlands, 94% of a representative sample of
chicken retail meat was contaminated with ESBL-produ-
cing E. coli isolates, of which 39% were also found in
human clinical samples tested in 31 microbiological
laboratories [92,93]. An association between the
approval of fluoroquinolones for use in food-producing
animals and the development of fluoroquinolone-
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resistant Salmonella and Campylobacter in animals and
humans has been observed in several countries
[31,94-96]. Reports of the spread of multidrug resistant
Salmonella Schwarzengrund from chickens to humans
in Thailand and from imported Thai food products to
humans in Denmark and the USA [97].
Use of antibiotics in food animals may result in the
deposition of residues in animal products and the
environment
• Consumption of antibiotic residues represents a poten-
tial threat to human health, through direct toxicity,
allergic reactions, or alteration of the bacterial flora pre-
sent in the human digestive tract [98].
• To safeguard humans from exposure to antibiotic-
added food, a withholding period must be observed
until the residues are no longer detected before the ani-
mal or animal products can be processed. Heavy respon-
sibility is placed on the veterinarian and livestock
producer to observe the period of withdrawal. In Eur-
ope, rapid tests are regularly performed to check the
absence of antibiotic residues in food.
• Eliminating the unnecessary usage of antibiotics
implies a change in mindset, integrating both long-term
public health concerns and productivity. This involves
everyone – from governments to producers to the con-
sumer. To stem the rising threat of resistant bacteria to
human health, there is an urgent need for regulation of
antibiotic usage in animals at the global level.
Additional file 3
The antibiotic pipeline is running dry
In the past, the discovery of potent new classes of anti-
microbials allowed to provide therapeutic options for
newly emerging AMR. During the 30 years following the
introduction of penicillin, scientists discovered a wide
range of antimicrobials to treat bacterial diseases. By the
early 1970s, 11 distinct antibiotic classes and more than
270 antibiotics had been brought into clinical use [99].
The process of novel antimicrobial discovery has slo-
wed to a virtual standstill. Most antimicrobials intro-
duced since the early 1970s have been chemical
modifications of previously discovered classes of drugs
[40]. The promise of genomics in discovering new anti-
biotic entities has remained largely unfulfilled to date.
Pharmaceutical companies have curtailed their anti-
infective research programmes
• Of the 15 companies with previous had antibiotic dis-
covery programmes, only 5 still maintain an active
research and development capacity in antibiotics [32].
• According to two recent reports from IDSA [33] and
the ECDC and EMEA [17], there are only a few candi-
dates in company pipelines.
• Only 15 antibiotics under development (mostly in
the early phases) present a new mechanism of action
with the potential to meet the challenge of multidrug
resistance. Of these, only two, both in the early develop-
ment phase, may be active against multidrug- resistant
Gram-negative bacteria, a group of bacteria causing ser-
ious therapeutic concerns due to their increasingly high
resistance to antibiotics.
Why is the antibiotic pipeline drying up?
The discovery and development of new antimicrobials is
an expensive and time-consuming process. Pharmaceuti-
cal companies must prioritize competing projects and
antibiotic development has a lower priority than other
competing drugs in the portfolio.
• In the late 1960s, infectious diseases were thought to
be conquered, opening the way for a shift in resources
to chronic conditions, such as cancer and cardiovascular
diseases.
• The limited duration of antibiotic treatments makes
them less profitable than other drugs prescribed for
years to treat chronic conditions, such as hypertension
and diabetes.
• There is strong competition with other drugs already
on the market. While resistance is an emerging problem,
low-priced generic antibiotics on the market are still
effective in treating most infections and are used as
first-line therapy.
• New antibiotics may be kept as last-resort treat-
ments, resulting in low sales for companies.
• New antimicrobials can also have a limited lifespan
because of the development of resistance.
• Modifications in regulatory procedures have been
perceived as having created an “unfriendly” environ-
ment. Regulators have been demanding demonstrations
of the relative efficacy of new antibiotics versus those
already registered within tighter statistical parameters, i.
e., shifting from “non-inferiority” to “superiority” trials
[40,100].
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